SLIL Biomedical Corp. is an early development-stage drug discovery company, devoted to discovering new treatments for cancers and other serious diseases. The Company has leveraged its extensive patent portfolio, its network of corporate, governmental and academic collaborations and its distinctive competencies in chemical synthesis and drug design, to discover and develop a substantial pipeline of prospective therapeutic drugs. Additionally, the Company has developed and holds the exclusive license to the 'Sequential Pathogenesis' technology platform - a proprietary new model that describes the involvement of modified human macrophages in disease-causation. Elucidation of this paradigm has already led to the discovery of a new, disease-associated virus, allowing for the identification of a range of novel therapeutic targets for drug discovery, and has led us to potential new diagnostics for important human diseases. SLIL has a strong board and well-qualified management. The Company also has outstanding scientific resources, led by Dr. Laurence Marton and Dr. Benjamin Frydman. Dr. Marton is considered a leading expert in the field of polyamines and their role in cell function and human disease, while Dr. Frydman is a world-renowned organic chemist and a leader in the field of porphyrin research.